Facebook
Twitter
LinkedIn
Forward
9th Annual Updates from ASH 2023: Practice Changing Abstracts
Chicago, IL US
March 1, 2024
Elevate Your Impact in Hematologic Oncology!
Join us for this not-to-miss event that brings together community-based providers and esteemed academic oncologists. Together, we will improve patient care and outcomes in hematologic malignancies.
Our mission is clear: To save lives. We're committed to achieving this by exploring cutting-edge treatment options and harnessing medical breakthroughs that will significantly reduce cancer-related fatalities. This includes delving into groundbreaking approaches like CAR T-cell therapy, innovative immunotherapies, and precision-targeted agents.
This activity will help healthcare professionals redefine the standard of care for both newly diagnosed patients and those facing relapsed blood cancers. It will empower them to stay at the forefront of their field by providing them with the latest scientific advancements, inspiring innovative ideas, and addressing the most pressing issues concerning patients afflicted with these diseases.
Together, let's make a real difference in the lives of those battling hematologic malignancies. Join us in shaping the future of hematologic oncology.
Learn more at the conference website!
Target Audience
This activity is designed for hematologists, medical oncologists, pathologists, fellow and resident trainees, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals dedicated to treating hematologic cancers.
Learning Objectives
After this activity, participants will be able to:
- Recall the optimal patient selection, timing, and regimens for stem cell transplantation with high-risk and relapsed/refractory disease;
- Recognize international trends in the care of hematologic malignancies;
- State the emerging treatment strategies, the role of targeted agents in therapeutic paradigms for patients with myeloid malignancies, and available clinical trial options and other approaches to patients with relapsed/refractory disease;
- Describe the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common benign hematologic diseases, including newly approved therapeutic classes;
- Discuss evolving treatment paradigms and therapy sequencing for novel agents in the care of patients with multiple myeloma, including approved and emerging CAR T-cell therapies, as well as bispecific antibodies with varied therapeutic targets;
- Illustrate how cutting-edge data presented at the 2023 Annual Meeting of the American Society of Hematology can apply to clinical practice;
- Interpret emerging clinical trial data in the context of CAR T-cell therapy for lymphoid malignancies and its place in evolving hematologic malignancy treatment standards;
- Evaluate available treatments for patients with lymphoma based on optimal treatment sequencing, novel agents and their role in earlier lines of therapy, and how these change best practices for evidence-based care of both newly diagnosed and relapsed/refractory cases.
You may also be interested in
SPEAKER | ||
8:30 AM | Fellows Meet the Expert | Raje Noopur, MD |
9:00 AM | Pharmacy Session | Jennifer Collins, PharmD |
9:30 AM | Concurrent Session: Fellows: Case-Based Clinical Trial Considerations | Alexandra Rojek, MD and Rafael Madero Marroquin, MD |
9:30 AM | Concurrent Session: APP / Nursing Session | Mylove Mortel, MSPH, RN |
10:30 AM | Break | |
11:00 AM | Keynote: Myeloma | Raje Noopur, MD |
12:00 PM | Lunch | |
1:00 PM | HL & NHL | Sonali Smith, MD |
1:30 PM | Break | |
1:45 PM | Non-Malignant Hematology | Kenneth Cohen, MD |
2:15 PM | Updates in Myeloid Diseases (Myelofibrosis, MPN, MDS) | Satyajit Kosuri, MD |
2:45 PM | Break | |
3:00 PM | Panel: CLL (CAR, co-op trials, BTKI tox) | Justin Kline, MD; Peter Riedell, MD; Michael Thirman, MD |
3:30 PM | International Perspectives on Hematology | Fatema Alkaabi, MD |
4:15 PM | Updates in Acute Leukemias (AML, ALL) | Mariam Nawas, MD |
4:45 PM | Closing Remarks | Michael Bishop, MD |
5:15 PM | ADJOURN | |
The agenda is subject to change.
Convene
333 N Green Street
Chicago, IL
60607
United States
HYBRID CONFERENCE
Participants can participate in person or virtually. For more information, contact Meeting Achievements via e-mail.
CONVENE
Convene at 333 North Green Street offers over 40,000 square feet of purpose-built meeting and event space for small to large programs. This property includes a dedicated meetings and events floor, sweeping views of downtown, optimal branding opportunities, and a unique design. The state-of-the-art meeting space is fully outfitted with seamless technology, an onsite AV team, and 5-star hospitality that will elevate your next meeting and event experience. Learn more at their website.
WANT TO KNOW MORE?
Learn more about the conference by visiting the conference website!VISITING CHICAGO
Discover why Condé Nast Traveler readers voted Chicago the Best Big City in the U.S. for a historic sixth year in a row. To help plan your stay in Chicago, visit choosechicago.com.
ACCESSIBILITY The University of Chicago is committed to providing equal access appropriate to need and circumstances and complies fully with legal requirements of the Americans with Disabilities Act. If you are in need of special accommodation, please contact our office via email at support@meetingachievements.com.
UNIVERSITY OF CHICAGO COURSE DIRECTOR
Michael R. Bishop, MDProfessor of Medicine
Director, Jonas Center for Cellular Therapy
Director, Hematopoietic Stem Cell Transplantation Program
KEYNOTE FACULTY
Noopur Raje, MDProfessor, Medicine
Director, Multiple Myeloma Program, Medical Oncology
Harvard University
UNIVERSITY OF CHICAGO PLANNING COMMITTEE
| Andrzej Jakubowiak, MD, PhD Professor of Medicine Director, Myeloma Program | Justin Kline, MD Associate Professor of Medicine Director, Lymphoma Program |
Rafael Madero Marroquin, MD Fellow, Hematology and Medical Oncology | Mylove Mortel, MSPH, RN, OCN Assistant Director, Transplant & Cell Therapy Clinical Operations |
Toyosi Odenike, MD Professor of Medicine Director, Leukemia Program | Alexandra Rojek, MD Fellow, Hematology and Medical Oncology |
Sonali Smith, MD Elwood V. Jensen Professor in Medicine Chief, Sections of Hematology/Oncology |
UNIVERSITY OF CHICAGO FACULTY
Kenneth Cohen, MD Assistant Professor of Medicine | Mariam Nawas, MD Assistant Professor of Medicine |
| Benjamin A. Derman, MD Assistant Professor of Medicine | Peter A. Riedell, MD Assistant Professor of Medicine |
Satyajit Kosuri, MD Assistant Professor of Medicine | Michael Thirman, MD Associate Professor of Medicine |
| Raje Noopur, MD Professor of Medicine |
Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 6.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credit
University of Chicago Medicine is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Participants who successfully complete the entire activity and complete an evaluation form will earn 6.50 contact hours.
American Board of Internal Medicine MOC II Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
American Board of Pediatrics MOC Part II Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.50 MOC points in the American Board of Pediatrics's (ABP) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.50 MOC points in the American Board of Pediatrics's (ABP) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.
Other Healthcare Professional Credit
Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
Please Note: The credit claiming process will close three months after the conference end date. Requests to claim credit after three months will be subject to additional fees.
REGISTRATION
Early rates expire on December 27, so reserve your spot today!
Profession Type | In Person | Virtual |
|---|---|---|
Physicians | $100/$125 | $50/$60 |
Nurses, Pharmacists, Other Healthcare Professionals | $45/$60 | $30/$40 |
Residents & Fellows with a verification letter | $25 | $25 |
| UChicago Faculty & Staff | $25 | $0 |
| Industry | $495 | $195 |
CANCELLATION POLICY Please see the registration site for the full details. | ||
Claiming Credit: After creating an account or logging in, enter the access code to unlock the credit claiming process.
Please Note: The credit claiming process will close three months after the activity ends. Requests to claim credit after three months will be subject to additional fees.
Please login or create an account to proceed.